 | Up a level |
Abdulsamad, Saud A, Naeem, Abdulghani A, Zeng, Hao, He, Gang, Jin, Xi, Alenezi, Bandar A, Ai, Jianzhong, Zhang, Jiacheng, Ma, Hongwen, Rudland, Philip S 
ORCID: 0000-0002-7491-0846 et al (show 1 more authors)
(2024)
Experimental treatment efficacy of dmrFABP5 on prostate cancer singly or in combination with drugs in use.
American journal of cancer research, 14 (1).
pp. 300-323.
Naeem, Abdulghani A, Abdulsamad, Saud A, Zeng, Hao, He, Gang, Jin, Xi, Zhang, Jiacheng, Alenezi, Bandar T, Ma, Hongwen, Rudland, Philip S ORCID: 0000-0002-7491-0846 and Ke, Youqiang ORCID: 0000-0001-5341-8644
(2024)
FABP5 can substitute for androgen receptor in malignant progression of prostate cancer cells.
International journal of oncology, 64 (2).
18-.
Naeem, Abdulghani A, Abdulsamad, Saud A, Rudland, Philip S ORCID: 0000-0002-7491-0846, Malki, Mohammed I and Ke, Youqiang ORCID: 0000-0001-5341-8644
(2019)
Fatty acid-binding protein 5 (FABP5)-related signal transduction pathway in castration-resistant prostate cancer cells: a potential therapeutic target.
PRECISION CLINICAL MEDICINE, 2 (3).
pp. 192-196.
Zhang, Jiacheng, He, Gang, Jin, Xi, Alenezi, Bandar T, Naeem, Abdulghani A, Abdulsamad, Saud A and Ke, Youqiang ORCID: 0000-0001-5341-8644
(2023)
Molecular mechanisms on how FABP5 inhibitors promote apoptosis-induction sensitivity of prostate cancer cells.
Cell biology international, 47 (5).
pp. 929-942.